Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
-
861“…Immunohistochemistry (IHC) using the validated anti ROR1 monoclonal antibody (4A5) was performed on the Australian Pancreatic Cancer Genome Initiative (APGI) cohort of PDAC samples (n = 152). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
862por Qiu, Dongmei, Kurosawa, Michiko, Lin, Yingsong, Inaba, Yutaka, Matsuba, Tsuyoshi, Kikuchi, Shogo, Yagyu, Kiyoko, Motohashi, Yutaka, Tamakoshi, Akiko“…Diabetes mellitus (DM) has increased the risk for pancreatic cancer in many studies. In the JACC Study, DM had a risk for pancreatic cancer in males (hazard ratio = 2.12). …”
Publicado 2005
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
863“…Colorectal cancer, lung cancer and pancreatic cancer are known as three major death-causing cancers in most countries. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
864
-
865“…Pancreatic cancer with bone metastasis is considered a very rare malignancy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
866por Zeng, Xiaohu, Zhu, Xin, Tian, Qikang, Tan, Xiaoke, Sun, Ning, Yan, Min, Zhao, Junwei, Wu, Xiangxiang, Li, Ruiqin, Zhang, Zhenqiang, Zeng, Huahui“…Cel-CSO enhanced the anticancer efficacy, promoted the circulation time of Celastrol, and reduced the subacute toxicity, which indicated that CSO can be a promising Celastrol delivery system for pancreatic cancer therapy.…”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
867por Yan, Tian-Bao, Huang, Jia-Qi, Huang, Shi-Yun, Ahir, Bhavesh K., Li, Long-Man, Mo, Zeng-Nan, Zhong, Jian-Hong“…Currently, surgical treatment is the only effective way to improve the survival of pancreatic cancer patients. Therefore, it is crucial to diagnose the disease as early as possible in order to improve the survival rate of patients with pancreatic cancer. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
868por Kim, Peter K, Halbrook, Christopher J, Kerk, Samuel A, Radyk, Megan, Wisner, Stephanie, Kremer, Daniel M, Sajjakulnukit, Peter, Andren, Anthony, Hou, Sean W, Trivedi, Ayush, Thurston, Galloway, Anand, Abhinav, Yan, Liang, Salamanca-Cardona, Lucia, Welling, Samuel D, Zhang, Li, Pratt, Matthew R, Keshari, Kayvan R, Ying, Haoqiang, Lyssiotis, Costas AEnlace del recurso
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
869por Kim, Dong UkEnlace del recurso
Publicado 2022
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
870por LaPelusa, Michael, Shen, Chan, Arhin, Nina D., Cardin, Dana, Tan, Marcus, Idrees, Kamran, Geevarghese, Sunil, Chakravarthy, Bapsi, Berlin, Jordan, Eng, Cathy“…SIMPLE SUMMARY: Pancreatic cancer is being diagnosed more frequently in younger individuals. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
871por Ming, Yue, Chen, Xia, Xu, Yuanpei, Wu, Yuanyuan, Wang, Chenlu, Zhang, Tingting, Mao, Renfang, Fan, Yihui“…RESULTS: 1,6-hexanediol significantly inhibited cell proliferation and induced cell death in all tested pancreatic cancer cells (BxPC-3, PANC-1, AsPC-1 and CFPAC-1) but had a minimal effect on control cells (HPDE6-C7) at low doses. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
872“…Pancreatic cancer is one of the most aggressive malignancies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
873por Levink, Iris J. M., Brosens, Lodewijk A. A., Rensen, Sander S., Aberle, Merel R., Olde Damink, Steven S. W., Cahen, Djuna L., Buschow, Sonja I., Fuhler, Gwenny M., Peppelenbosch, Maikel P., Bruno, Marco J.“…INTRODUCTION: Factors underlying antitumor immunity in pancreatic cancer (PC) are poorly understood. We hypothesized that not neoantigen quantity, but quality, is related to immune cell infiltration and survival. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
874“…SIMPLE SUMMARY: This review article presents a synopsis of the key clinical developments, their limitations, and future perspectives in the treatment of pancreatic cancer. In the first part, we summarize the available treatments for pancreatic cancer patients according to tumor stage, as well as the most relevant clinical trials over the past two decades. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
875por Takikawa, Tetsuya, Kikuta, Kazuhiro, Hamada, Shin, Kume, Kiyoshi, Miura, Shin, Yoshida, Naoki, Tanaka, Yu, Matsumoto, Ryotaro, Ikeda, Mio, Kataoka, Fumiya, Sasaki, Akira, Nakagawa, Kei, Unno, Michiaki, Masamune, AtsushiEnlace del recurso
Publicado 2022
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
876
-
877“…SIMPLE SUMMARY: Pancreatic cancer ranks as the seventh leading cause of cancer-related death worldwide. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
878por Pijnappel, Esther N., Dijksterhuis, Willemieke P. M., Sprangers, Mirjam A. G., Augustinus, Simone, de Vos-Geelen, Judith, de Hingh, Ignace H. J. T., Molenaar, Izaak Q., Busch, Olivier R., Besselink, Marc G., Wilmink, Johanna W., van Laarhoven, Hanneke W. M.“…PURPOSE: It is plausible that patients with pancreatic cancer experience fear of tumor recurrence or progression (FOP). …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
879por Li, Ying, Wang, Jing, Wang, Haiyan, Zhang, Shaoqiang, Wei, Yingxin, Liu, Shanglong“…Tumor-promoting inflammation and tumor-suppressive immunity are two main characteristics of the tumor microenvironment in pancreatic cancer. Yet, the mechanism of inflammation and immune response in pancreatic cancer development is still unclear due to the dual role of some cytokines and the complicated crosstalk between tumor and stromal components in TME. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
880“…There are two main factors that drive these advancements to facilitate treatment of patients with pancreatic cancer, ranging from direct locoregional therapy to palliation of symptoms related to inoperable pancreatic cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto